Veru Inc., a biopharmaceutical company, operates through two segments, Commercial and Research and Development. The Commercial segment offers FC2 female condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. This segment sells its products directly to consumers through its e-commerce Website, as well as through third-party distributors and retail pharmacies. The Research and Development segment is involved in the development of TADFIN (tadalafil and finasteride combination) for the treatment of men with benign prostatic hyperplasia and erectile dysfunction; and VERU-111, a novel oral alpha and beta tubulin inhibitor, which is in Phase 1b/2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.